IP Library Patent Application 15275177
Patent Application
App. No. 15/275,177

HYDROXYBUPROPION AND RELATED COMPOUNDS AS MODULATORS OF DRUG PLASMA LEVELS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/275,177
Abstract

This disclosure relates to methods administering bupropion in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion are also disclosed.

Claims (30)

1 . A method of decreasing seizure risk associated with use of a bupropion comprising co-administering to a human being the bupropion with a dextromethorphan once or twice daily for at least four weeks; wherein co-administering the bupropion with the dextromethorphan results in a decreased risk of seizure while maintaining efficacy as compared administering 150 mg of the bupropion twice daily for at least four weeks without the dextromethorphan.

2 . The method of claim 1 , wherein the combination is administered twice a day.

3 . The method of claim 1 , wherein at least about 40 mg of the dextromethorphan is administered twice a day.

4 . The method of claim 1 , wherein about 50 mg to about 140 mg of the bupropion is administered twice a day.

5 . The method of claim 1 , wherein 44 mg to 46 mg of the dextromethorphan is administered twice a day.

6 . The method of claim 1 , wherein 100 mg to about 105 mg of the bupropion is administered twice a day.

7 . The method of claim 3 , wherein 100 mg to about 105 mg of the bupropion is administered twice a day.

8 . The method of claim 2 , wherein the dextromethorphan C max on the eighth day that the combination is administered, is at least about 40 ng/mL.

9 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 45 ng/mL to about 50 ng/mL.

10 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 50 ng/mL to about 60 ng/mL.

11 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 60 ng/mL to about 70 ng/mL.

12 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 70 ng/mL to about 90 ng/mL.

13 . The method of claim 7 , wherein the C max of the dextromethorphan on the eighth day is about 80 ng/mL to about 90 ng/mL.

14 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 80 ng/mL to about 100 ng/mL.

15 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 100 ng/mL to about 120 ng/mL.

16 . The method of claim 1 , wherein the C max of the dextromethorphan on the eighth day is about 120 ng/mL to about 140 ng/mL.

17 . The method of claim 1 , wherein the dextromethorphan contains deuterium.

18 . The method of claim 2 , wherein the bupropion C max on the eighth day that the combination is administered, is at least about 50 ng/mL.

19 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 50 ng/mL to about 60 ng/mL.

20 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 60 ng/mL to about 70 ng/mL.

21 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 70 ng/mL to about 80 ng/mL.

22 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 80 ng/mL to about 90 ng/mL.

23 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 90 ng/mL to about 100 ng/mL.

24 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 100 ng/mL to about 110 ng/mL.

25 . The method of claim 1 , wherein the C max of the bupropion on the eighth day is about 100 ng/mL to about 150 ng/mL.

26 . The method of claim 1 , wherein the bupropion contains an enantiomeric excess of R-bupropion or S-bupropion.

27 . The method of claim 2 , wherein the C max of the dextromethorphan on the first day that the combination is administered, is at least about 1.0 ng/mL.

28 . The method of claim 2 , wherein the C max of the dextromethorphan on the first day is about 1.5 ng/mL to about 20 ng/mL.

29 . The method of claim 2 , wherein the C max of the bupropion on the first day that the combination is administered, is at least about 40 ng/mL.

30 . The method of claim 2 , wherein the C max of the bupropion on the first day that is about 45 ng/mL to about 120 ng/mL.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 041510/0424 →